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Abstract
Background: Parkinson's disease (PD) is a chronic neurodegenerative disease which at present
has no cure, and it usually results in severe disability. The burden of PD increases as the illness
progresses, resulting in the extensive utilisation of both health and community services. Knowledge
of healthcare use patterns and of their determinants may greatly contribute to improve patient
care, however few studies have examined this issue in PD. The present study was devised to
describe the type of and reasons for medical healthcare resource use in persons with PD attending
a Centre for PD and Movement Disorders, and to examine drug prescriptions issued on such
occasions.
Methods: The study was a retrospective, cross-sectional survey in a cohort of ambulatory patients
with PD, conducted by means of standard interviews.
Results:  In the year before the study, 92 (70.8%) of 130 patients used medical healthcare
resources: 1/5 of the patients was admitted to hospital, 1/5 to emergency room, 2/5 were visited
by a non-neurology specialist, and 1/4 by the GP. Reasons were: nearly 20% programmed hospital
admissions and visits, and more than 25% injuries and musculo-skeletal diseases. Other conditions
typically occurring in PD (e.g. dementia, diabetes and cardio- and cerebro-vascular disease) were
less frequently involved. On such occasions, drugs for PD were occasionally changed, however drug
prescriptions for other indications were issued to more than 66% of the patients.
Conclusion: Several physicians other than the neurologist may take care of PD patients on
different occasions, thus emphasising the need for communication between the reference
neurologist and other physicians who from time to time may visit the patient.
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Background
Parkinson's disease (PD) is a neurodegenerative disease
which at present has no cure, and, despite the variety of
pharmacological and surgical treatment options [1-3], it
usually results in severe disability. In Europe, age-adjusted
prevalence rates of PD have been estimated at 1.6 per 100
population, with a steady increase in older groups, up to
3.5–3.6 in people aged 80 years and older [4]. Similar esti-
mates have been reported for the United States [5]. In
view of the increasing number of elderly people in devel-
oped countries, the prevalence of PD is expected to
increase, as well.
Because PD is a chronic condition, the disease burden
increases as the illness progresses, due to the appearance
of both disease- and drug-related problems, resulting in
the extensive utilisation of both health and community
services [6-10]. The high rate of prevalent comorbid con-
ditions occurring in PD, either associated or unrelated,
significantly contributes to the utilisation of healthcare
resources [11], which is higher than in subjects without
PD [8] and has substantial economic implications [12]. As
a consequence, it can be easily predicted that over the next
few years more PD patients will use more healthcare
resources, with a significant impact on the healthcare
systems.
Knowledge of healthcare use patterns and of their deter-
minants may greatly contribute to improve patient care,
providing physicians, caregivers and politicians with
information useful to estimate patient needs and to plan
intervention strategies and allocation of resources. At
present only few studies have examined healthcare use in
PD patients and its relationship with potentially relevant
factors, either related to the patient, such as age, sex and
other social and demographic characteristics, or to the dis-
ease itself, such as severity, duration and comorbidity
[8,11,13].
In the context of a project aimed at investigating health-
care needs, comorbidity, and drug use in PD patients, we
previously reported that in PD patients attending a neuro-
logical service drug prescribing patterns may be associated
with both disease- and patient-related factors, and that
analysis of drug prescriptions may help to identify major
comorbid conditions [14]. Since it was suggested that PD
patients seen primarily by a neurologist may have an
increased use of resources [15], as a logical extension of
our previous work, we decided to investigate the use of
healthcare resources in our cohort of ambulatory PD
patients. However, as we were not interested in perform-
ing a formal cost-of-illness study, but rather to focus on
the practical care of the patient, we directed our attention
to medical healthcare resource use, with particular regard
to the consequences for drug treatments. Regarding
resource data collected, we decided to focus on hospital
and emergency room (ER) admissions, and general prac-
titioner (GP) and non-neurologist specialist visits, as
these are the circumstances when physicians other than
the neurologist take care of PD patients.
Our specific aims were: to assess the reasons for medical
healthcare use, to look for possible relationship between
the medical healthcare use and the pattern of anti-Parkin-
son drug (APD) medications, and to assess drug prescrip-
tions issued by other physicians. All these aspects have so
far received little attention, despite their straightforward
relevance for the care of PD patients.
Methods
The present study is part of a cross-sectional survey of PD
outpatients consecutively attending the Centre for PD and
Movement Disorders of the Neurological Service of the
Ospedale di Circolo of Varese (Italy). The diagnosis of PD
was established by neurologists skilled in movement dis-
orders, according to the United Kingdom Parkinson's Dis-
ease Society Brain Bank Criteria [16]. Parkinsonisms
resulting from other degenerative conditions or secondary
to drugs, metabolic disorders or exposure to toxins were
excluded. All the participants in the study gave informed
consent.
Information about medical healthcare use over the previ-
ous year were obtained during a standard interview with
the patient and/or her/his caregiver(s), by using self-
report questionnaires. Medical healthcare resources
addressed included: hospital admissions, ER admissions,
GP and/or non-neurologist specialist visits (excluding
therefore programmed neurological visits directly related
to the follow-up of PD). Information was specifically
sought about: the number of times each medical health-
care resource was used, the reasons for use, the occurrence
on such occasions of modifications of the APD treatment
and the prescription of drugs for indications other than
PD (non-APDs). Collected information also included: the
main patient demographic and clinical data (i.e. sex, age,
age at onset and duration of PD), severity of PD, scored
according to the Hoehn and Yahr (H&Y) scale [17], infor-
mation about current drug treatments.
Data were stored in a database for subsequent analysis. To
ensure confidentiality, patients' names were not recorded
and a unique personal identification code was used to per-
form data linkage. Reasons for medical healthcare
resource use as well as indications for drug use were coded
using the International Classification of Diseases, 9th revi-
sion, Clinical Modifications (ICD-9-CM) [18], whereas
drugs were classified according to the Anatomical, Thera-
peutic and Chemical (ATC) classification index [19].BMC Health Services Research 2005, 5:26 http://www.biomedcentral.com/1472-6963/5/26
Page 3 of 8
(page number not for citation purposes)
Statistics
Results are presented as mean ± SD (unless otherwise
stated) with n indicating the number of observations.
Analysis of the data was performed on the whole patient
population and on groups of patients stratified according
to: decades of age and age at onset of PD, years of PD
duration, and H&Y stage. Statistical significance of the dif-
ferences between groups was assessed by use of parametric
(Student's t test or ANOVA followed by Tukey-Kramer
Multiple Comparisons post test) or non-parametric
(Kruskal-Wallis analysis followed by Dunn's Multiple
Comparison test) tests, according to the results of a pre-
liminary normality test. Frequency distribution differ-
ences were analysed using contingency tables and the χ 2
test or the Fisher's exact test, as appropriate. All the statis-
tical calculations were performed by use of a commer-
cially available statistical software (GraphPad Prism
version 3.0 for Windows, GraphPad Software, San Diego
California USA, http://www.graphpad.com).
Results
Use of medical healthcare resources
The study included 130 persons with PD, 69 females and
61 males. Their characteristics are shown in Table 1. Fifty
four patients (41.5% of total patients) had dyskinesia and
88 (67.7%) referred fluctuations of motor performances,
including wearing off and on off phenomena, while 42
subjects (32.3%) were non fluctuators. Ten patients
(7.7%) were taking antipsychotics for hallucinations, 22
(16.9%) were treated with antidepressants, 38 (29.2%)
received anxiolytics. All these drugs were prescribed and
managed by the neurologist of the Centre for PD. There
was no significant difference between females and males
with respect to any of the characteristics considered (data
not shown). In the previous year, 92 out of 130 patients,
corresponding to the 70.8% of all the patients, used one
or more medical healthcare resources (1.9 ± 1.1 resources/
patient, range 1–5). There was no significant difference
between patients using and not using medical healthcare
resources (Table 1). However, among patients using
resources both age at onset of PD and PD duration were
significantly different according to the type of resource
used (Table 2). This finding was further supported by
stratified analysis of the patients, inasmuch as 35.8% of
the patients aged at onset of PD 60 years or more had at
least a GP visit vs 12.2% in patients with earlier PD onset
(P = 0.0040), and 41% of the patients with disease dura-
tion longer than 8 years were admitted to ER vs 13.5% of
those with shorter disease duration (P = 0.0190). Other
significant differences were: 75% of the patients aged
more than 60 years used any type of resources vs. 50% of
the younger ones (P = 0.0129), 35.4% of the patients aged
70 years or more and 50% of those in H&Y stage IV had at
Table 1: Characteristics of the patients
Overall Resource use
yes no
patients, n (%) 130 (100) 92 (70.8) 38 (29.2)
age (years) 68.6 ± 10.0 (38–87) 69.4 ± 9.1 (45–86) 66.6 ± 11.7 (38–87)
age at onset of PD (years) 61.7 ± 10.2 (36–84) 62.3 ± 9.0 (40–84) 60.1 ± 12.7 (36–82)
PD duration (years) 6.9 ± 4.5 (1–24) 7.1 ± 4.8 (1–24) 6.5 ± 3.8 (1–14)
H&Y stage 2.6 ± 1.0 (I-IV) 2.7 ± 1.0 (I-IV) 2.5 ± 0.9 (I-IV)
Data are means ± SD (min-max), unless otherwise indicated.
Table 2: Characteristics of the patients according to the use of medical healthcare resources
Hospital admissions ER admissions Specialist visits GP visits P
resources used, n 29 31 74 42
patients, n (%) 25 (19.2) 29 (22.3) 54 (41.5) 35 (26.9)
resources/patient, mean (range) 1.2 (1–3) 1.1 (1–2) 1.4 (1–3) 1.2 (1–3)
patient characteristics
age (years) 71.0 ± 9.4 (45–86) 68.1 ± 9.0 (47–83) 68.6 ± 9.1 (45–85) 72.9 ± 7.7 (54–85) Ns
age at onset of PD (years) 64.3 ± 9.4 (40–84) 58.7 ± 7.3* (42–72) 62.0 ± 8.6 (40–80) 64.1 ± 7.5 (50–78) 0.037
PD duration (years) 6.7 ± 3.5 (2–20) 9.4 ± 3.8# (2–20) 6.6 ± 3.7 (1–24) 8.8 ± 4.6 (1–24) 0.004
H&Y stage 2.8 ± 0.9 (I-IV) 3.0 ± 1.0 (I-IV) 2.5 ± 1.0 (I-IV) 3.0 ± 1.0 (I-IV) Ns
Data are means ± SD (min-max), unless otherwise indicated.
* = P < 0.05 vs GP visits; # = P < 0.05 vs specialist visits.BMC Health Services Research 2005, 5:26 http://www.biomedcentral.com/1472-6963/5/26
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least a GP visit vs. 18.5% of younger patients (P = 0.0471)
and 20.6% in those in lower stages (P = 0.0191).
As regards patient gender, there were no major differences.
However, stratified analysis revealed minor differences, as
described hereafter:
- the frequency of hospital admissions was significantly
higher in males than in females in H&Y stage III (28.6%
vs 3.8%, P = 0.0347) and in the age interval 70–79 years
(33.3% vs 6.9%, P = 0.0407);
- among females hospital admissions were more common
in patients in H&Y stage II (30.8% vs 7% of patients in
other stages, P = 0.0405), while among males they were
more frequent in H&Y stage IV (47.1% vs 11.4% in lower
stages, P = 0.0194);
- in males (but not in females) the frequency of ER admis-
sions and GP visits increased with increasing PD duration
(52.6% and 42.1% of the male patients with disease dura-
tion longer than 8 years vs 9.5% and 11.9% with shorter
disease duration, P = 0.0068 and P = 0.0048 respectively).
Reasons for medical healthcare resource use
According to the ICD-9-CM classification [18], the most
common causes for resource use were represented by pro-
grammed hospital admissions and control visits, which
were included in the category 'supplementary classifica-
tion of factors influencing health status and contact with
health services'. The next most frequent category were
symptoms, signs and ill-defined conditions, collecting
several complaints which could not be precisely assigned
to other more specific categories. Injuries were 23 cases in
total and included 10 fractures and 11 ER admissions for
injuries due to falls. Table 3 collects detailed information
about all the reasons for medical healthcare resource use
recorded in the present study.
Relationship between use of medical healthcare resources 
and APD treatment patterns
Patients treated with levodopa alone or associated with
other APDs were respectively 62 and 66, and they did not
differ in the overall frequency of healthcare resource use
(75.8% vs 65.1%). As regards the frequency of use of spe-
cific medical healthcare resources, more patients on levo-
dopa alone had GP visits than those on levodopa
associated with other APDs (37.1% vs 18.2%, P = 0.018).
No significant differences were found in the frequency of
hospital admissions (21.0% vs 16.7%), ER admissions
(43.5% vs 39.4%), or specialist visits (21.0% vs 22.7%).
The only two patients on DA agonists alone both used
medical healthcare resources: one was admitted to hospi-
tal and to ER (on separate occasions), and the other had
two different (and separate) specialist visits.
Drug prescription during medical healthcare resource use
APD treatments: A total of 11 patients (8.5% of total
patients) had modifications of their APD treatment, most
often during hospital admissions (6 patients), followed
by specialist visits (2), GP visits (1 patient) and ER admis-
sions (1 patient). More than one third of hospital admis-
sions (11 out of 29, 37.9%) therefore resulted in changes
of APD treatment (6 dose increased, 2 dose decreased, 2
drug withdrawn, 1 new prescription), which on the con-
trary occurred only occasionally as a consequence of spe-
cialist visits (1 dose decreased, 2 new prescriptions) or GP
visits (2 drug withdrawn). Levodopa was the drug most
frequently changed (10 prescription changes, including 3
dose increased, 2 dose decreased, 2 new prescriptions, and
2 drug withdrawn), while on the whole prescriptions of
DA agonists were changed on 7 occasions (3 dose
increased, 1 dose decreased, 1 new prescription, and 2
drug withdrawn). On one occasion there were no infor-
mation concenring the specific type of change. Non-APD
treatments: Prescriptions of non-APDs were issued to 86
patients (66.1% of total patients), most often during ER
admissions and GP visits (37 and 36 patients, respec-
tively), followed by specialist visits (13 patients). Most
prescribed drugs were (ATC first level): general antiinfec-
tives (J, 15 patients), musculo-skeletal system drugs (M,
14 patients), drugs for the alimentary tract and metabo-
lism and for the cardiovascular system (A and C, both 11
patients). Information about occasions in which non-
APDs were prescribed are given in Table 4. Data about pre-
scriptions of non APDs during hospital admissions were
not analysed since nearly all the patients and/or their car-
egivers were unable to report affordable information con-
cerning this particular issue.
Discussion
The results of this study allowed to describe the type of
and reasons for medical healthcare use in patients with
PD referring to a neurological service dedicated to move-
ment disorders, and to examine the role of patient- and
disease-related factors, with particular regard to the pat-
tern of APD treatment. In addition, the changes of APD
medications and non-APD prescriptions as consequences
of medical healthcare use were also specifically analysed.
A few points need to be preliminarily discussed about our
data. First, this was a survey of PD outpatients attending a
service devoted to movement disorders. But it also means
that only persons who were ambulant or able to reach an
outpatient service have been considered, and subjects
with H&Y score over IV, which means in the very
advanced stages of the disease, have not been included.
Second, data collection was accomplished by
retrospective self-report of events occurring in the previ-
ous 12 months, and it is possible that some respondents
had difficulty in accurately reporting such information,BMC Health Services Research 2005, 5:26 http://www.biomedcentral.com/1472-6963/5/26
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even if most of these patients are known to carefully keep
the documents concerning their health. Being aware of
this potential bias, we sought only information that could
be expected to be recalled with some degree of accuracy,
therefore excluding e.g. drug prescriptions in hospital.
Moreover, whenever possible, we cross-compared
reported information with patient records in our service
(e.g., in the case of medical healthcare resource use for
symptoms, signs and ill-defined conditions and for inju-
ries) and concluded that only negligible, if any, bias was
introduced by inaccuracy of collected information.
According to our results, the most utilised medical health-
care resource were specialist visits (41.5% of the patients),
followed by GP visits (26.9%), ER admissions (22.3%),
and hospital admissions (19.2%). Consultations and hos-
pital admissions for reasons related to PD were a priori
excluded from our survey. However, according to the
records of our service during the previous year, only 14
patients (11.5% of total patients) were admitted to the
hospital for reasons related to the disease and requiring
more careful clinical observation and drug changes, while
the mean year frequency of visits for PD was 2.1 (range: 1–
Table 3: ICD-9-CM classification of the reasons for medical healthcare resource use
Hospital admissions ER admissions Specialist visits GP visits Total %
factors influencing 
health status and 
contact with health 
services (V01–V83)
rehabilitation (4) = rehabilitation (5); 
problems of eye (7), 
heart (3), diabetes (2), 
urogenital (2), skin (1); 
Rx of hip (1)
general control (8); 
urinary cathether 
substitution (1)
34 19.3
symptoms, signs, 
and ill-defined 
conditions (780–799)
chest pain (2); sleep 
disturbance (1); 
epistaxis (1); abdominal 
pain (1)
abdominal pain (2); 
dyskinesia (1); epistaxis 
(1); dysphagia (1)
abdominal pain (6); 
hallucination (1); 
headache (1)
abdominal pain (2); 
hallucination (1); cough 
(1); nausea, vomiting 
(1); urinary 
incontinence (1)
24 13.7
injury (800–959) fracture of femur (1), 
femur plus humerus (1)
injuries due to falls (11); 
fractures: ribs (2), wrist 
(1), upper limb (1), foot 
(1), unspecified (2); 
open wound (1)
= fracture unspecified (1); 
open wound (1)
23 13.1
diseases of musculo-
skeletal system and 
connective tissue 
(710–739)
osteoarthrosis (1) pain in joint (1); 
lumbago (1)
intervertebral 
discopathy (3); lumbago 
(3); pain in joint (2); 
osteoarthrosis (2); 
spondilosis (1); 
osteomyelitis (1)
pain in joint (4); 
lumbago (2); 
rheumatism (1)
22 12.5
diseases of the 
circulatory system 
(390–459)
acute hypotension (2); 
cerebral ischemia (1); 
aortic aneurysm (1)
= hypertension (3); 
ischemic heart disease 
(2); atrial fibrillation (1); 
myocardial 
degeneration (1); aortic 
aneurysm (1); varicous 
veins (1)
hypotension (2); 
hypertenson (1)
16 9.1
diseases of the 
nervous system and 
sense organs (320–
389)
cataract (3) hearing loss (1) tinnitus (1); presbyopia 
(1); cataract (1); hearing 
loss (2); glaucoma (1); 
impacted cerumen (1)
conjunctivitis (2); 
vertiginous syndrome 
(1)
14 7.9
diseases of the 
digestive system 
(520–527)
abdominal hernia (2); 
gastric ulcer (1); 
constipation (1); 
cholelithiasis (1)
pulp disease (1); teeth 
extraction (1)
avulsions of teeth (2); 
periodontal disease (1)
constipation (2); 
intestinal obstruction 
(1); cholelithiasis (1)
14 7.9
diseases of 
respiratory system 
(460–519)
pneumonia (1) pneumonia (1) asthma (1) influenza (5); acute 
laringytis (1)
95 . 1
other* 411 3 22 0 1 1 . 4
Total 29 31 74 42 176 100.0
* = encompasses the following ICD-9-CM categories (which individually accounted for less than 5% of total medical healthcare resource use): 
neoplasms (140–239), n = 8, 4.5%; diseases of genitourinary system (580–629), 7, 4%; diseases of skin (680–709), 3, 1.7%; infectious and parasitic 
diseases (001–139), 1, 0.7%; mental diseases (290–319), 1, 0.7%.BMC Health Services Research 2005, 5:26 http://www.biomedcentral.com/1472-6963/5/26
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7). Other studies reported on average 5.4 medical visits
and 2.7 inpatient hospital days in 6 months [15], or 6.0
physician consultations (including neurologist and other
physicians) per year, and no hospital days and ER visits
[8]. De Boer et al. [13] showed that nearly half of the
patients had at least a GP visit in the previous 6 months.
In comparison our patients require less consultations by
GPs or non-neurological specialists, possibly due to the
preferential consultation of the Centre for PD and Move-
ment Disorders of their reference. On the other side, they
seem to use more frequently hospital and ER services,
although without any apparent relationship with patient
and/or disease characteristics. This finding was quite
unexpected, since disease severity is usually pointed to as
one of the major predictors of increased healthcare use in
PD [13,20-22]. Another study [10] however reported that
disease severity better predicted non medical rather than
medical needs.
In the present study, differences according to patient and
disease characteristics regarded mainly the specific type of
resource used (Table 2). In particular, patients admitted to
hospital or consulting GP were slightly older at onset of
PD, while those admitted to ER had longer disease
duration, suggesting that need for hospital and/or GP care
is related mainly to age, while disease duration is rather
involved in acute comorbid events leading to ER admis-
sion. Further support to this suggestion comes from the
observation that the most frequent causes of ER admis-
sions were injuries (19, 61.3% of total ER admissions),
mainly fractures (7, 36.8% of total injuries), which are
typical complications in the advanced stages of the disease
[23]. A recent study [24] comparing PD with old-age ver-
sus middle-age onset evidenced greater motor impair-
ment in subjects with old-age onset, pointing to the
possible role of age and comorbidities. On the other hand
another study [25] describes similar severity and disability
in patients with onset of the disease before 50 years and in
persons with PD onset after 50 years, giving relevance to
social and psychosocial factors in contributing to the
impairment of quality of life. A final consideration can
concern the comparison of our data with the ones con-
cerning healthcare utilisation by a sample of 5000 UK
population aged 65–90, showing that almost 80% of
them visited a GP at least once a year and overall, women
used more ambulatory care services and men hospitalised
more often [26]. Similar data concerning hospitalisation
were found in our cases, although we were not able to
confirm the tendency of female patients to seek more
often GP assistance. Differences in the overall organisa-
tion of the National Healthcare System between Italy and
UK might however account for such a discrepancy.
Indeed, only in males we observed a correlation between
PD duration and the frequency of ER admissions and GP
visits, possibly in line with the gender differences in the
clinical aspects of the disease, with more severe motor
impairment and behavioural problems in men [27].
Although it is well established that PD is often compli-
cated by a burden of comorbid conditions, ranging from
psychiatric disturbances [28] to bladder dysfunctions
[29], relatively few studies exist which address the issue of
comorbidity in PD from a comprehensive point of view.
In the present study, we selectively targeted only those
comorbid conditions which resulted in the use of medical
healthcare resources, to address specifically how comor-
Table 4: Non-APD prescriptions issued on the occasion of medical healthcare resource use
ATC (first level) ER admissions Specialist visits GP visits
A – alimentary tract and metabolism 2 (2) 3 (2) 9 (7)
B – blood and blood forming organs 5 (5) 2 (2) =
C – cardiovascular system 6 (6) = 5 (5)
D – dermatologicals 2 (2) = 1 (1)
G – genitourinary system and sex hormones 4 (3) = 1 (1)
H – systemic hormonal preparations, excluding sex hormones 2 (2) = =
J – general antiinfectives for systemic use 6 (5) 4 (4) 7 (6)
L – antineoplastic and immunomodulating agents = 3 (3) =
M – musculo-skeletal system 6 (5) 5 (4) 7 (5)
N – nervous system = 1 (1) 5 (5)
P – antiparasitic products, insecticides and repellents = = =
R – respiratory system 2 (1) = 5 (4)
S – sensory organs 2 (2) = 2 (1)
V – various 1 (1) 1 (1) =
Other 4 (4) = 1 (1)
Total 41 (37) 15 (13) 43 (36)
Data expressed as number of prescriptions and as number of patients (in parentheses).BMC Health Services Research 2005, 5:26 http://www.biomedcentral.com/1472-6963/5/26
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bidity impacts on medical healthcare use in PD patients.
As a consequence, our results reflect the pattern of comor-
bid diseases which are serious enough to warrant medical
intervention, and therefore may have a major impact on
the general patient care. In this regard, it is of interest that
three categories of disease conditions, namely symptoms
and signs and ill-defined conditions, injuries, and dis-
eases of the musculo-skeletal system, account for nearly
40% of all reasons for resource use (Table 3). Symptoms,
signs and ill-defined conditions include mainly condi-
tions such as abdominal pain due to constipation, sleep
disturbance, hallucination, headache, dyskinesia, dys-
phagia, all representing likely complications of the course
of PD, as also falls and fractures and lumbago and pain in
joint [1,3]. It follows that in these persons more than 1
out of 3 reasons for medical healthcare resource use is jus-
tified by PD itself together with its burden of complica-
tions, while other conditions typically occurring with high
frequency in PD patients, such as dementia, diabetes and
cardio- and cerebrovascular disease [11]. On the other
hand, psychiatric disturbances (hallucinations) in this
sample accounted for only 1 specialist and 1 GP consulta-
tion, which seem quite low figures, in comparison to the
known frequency and severity of such ailment in PD
patients [12,13]. We have no exhaustive explanations for
this finding, however it cannot be excluded that the man-
agement of the patients by a PD-dedicated centre may
contribute to minimize the problems related to the dis-
ease and its therapy.
In the present study, we found no apparent correlation
between resource use and APD treatments, with the only
exception of a positive correlation between levodopa
medication and GP visits. However, we believe that this is
a spurious association, due to the fact that in our cohort
PD patients on levodopa in association with other APD
drugs or on DA agonists alone were significantly younger
and had an earlier onset of PD than patients on levodopa
alone [14]. This finding is in line with the study by Died-
erich et al. [24], which was performed in a similar popu-
lation of patients referring to a centre for movement
disorders. The preferential use of association treatments,
or even of therapy with DA agonists alone [30], is thought
to prevent the motor complications associated with long-
term levodopa treatment [31]. Interestingly however, in
the present investigation no significant difference was
found in medical healthcare use according to the various
patterns of APD medication, i.e. levodopa alone, levo-
dopa associated with other APD (mainly DA agonists), or
DA agonists alone. It cannot be excluded that the fact that
the present patient sample refers to a centre for PD and
movement disorders may account for an optimisation of
individual therapeutic schemes, possibly leading to a
reduced risk of complications.
An additional objective of our investigation was the study
of drug prescriptions on the occasions of medical health-
care resource use. According to our results, APD treat-
ments were modified in 8.5% of the patients, mainly
(55% of the cases) during hospital admissions. Levodopa
was the drug most frequently modified (59% of the
cases). Considering that in the present population APD
treatments account for 307 prescriptions [14], the total
number of prescriptions changed (17, 5.5% of total pre-
scriptions) may be considered low. It seems thus that APD
treatment remains primarily the responsibility of the neu-
rologist. On the contrary, as for non-APD treatments we
found that a total of 99 prescriptions were issued to 86
patients (66% of total patients), which look as very high
figures. GP (43% of total prescriptions) and ER (41%)
were the main responsible for such prescriptions. While
prescriptions on the occasions of ER admissions are more
likely to reflect acute and intercurrent needs, prescriptions
by GP may reflect the need to treat chronic illness,
although this speculation should be specifically addressed
in ad hoc studies. Taking in mind that in our previous
study [14] we found in this cohort of patients 252 non-
APD prescriptions, the present results suggest that physi-
cians other than the reference neurologist are responsible
for a significant fraction of such prescriptions, and further
emphasise the need for an accurate update of the patient
files on the occasions of control visits, as well as for a con-
tinuous communication between the reference neurolo-
gist and other physicians who from time to time may take
care of the patient.
Conclusion
In summary, we have described the type of and reasons for
medical healthcare use during 12 months in a cohort of
patients with PD referring to a neurological service dedi-
cated to movement disorders. According to our results,
major determinants of resource use are programmed hos-
pital admissions and visits, injuries and diseases of the
musculo-skeletal system; new drug prescriptions (mainly
non-APD drugs) are a common occurrence on the occa-
sions of resource use. Optimisation of the global assist-
ance to patients, including prevention of traumatic
accidents, could therefore result effective to reduce and
rationalise resource use. The need for careful periodical
check of drug treatments is also emphasised.
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